Altimmune, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2836 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - Aug 6th, 2026 9:22 am
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus - Aug 5th, 2026 9:10 am
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses - Aug 5th, 2026 9:08 am
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Aug 5th, 2026 6:00 am
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - Aug 3rd, 2026 6:00 am
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data - Jul 29th, 2026 5:00 am
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - Jul 28th, 2026 12:42 pm
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial - Jul 28th, 2026 8:04 am
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Jul 28th, 2026 6:33 am
Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results - Jul 28th, 2026 6:22 am
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Jul 28th, 2026 5:00 am
US Research house initiates Solvonis coverage citing differentiated addiction strategy - Jul 13th, 2026 3:10 am
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market - Jul 5th, 2026 4:08 pm
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - Jun 26th, 2026 2:59 am
5 Small Drug Stocks to Invest in Amid a Biotech Comeback - Jun 25th, 2026 6:40 am
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? - Jun 24th, 2026 7:26 am
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data - Jun 17th, 2026 9:16 am
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? - Jun 12th, 2026 9:30 am
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near - Jun 10th, 2026 7:05 am
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - Jun 8th, 2026 11:00 am